256 related articles for article (PubMed ID: 23980093)
1. Integrative radiogenomic profiling of squamous cell lung cancer.
Abazeed ME; Adams DJ; Hurov KE; Tamayo P; Creighton CJ; Sonkin D; Giacomelli AO; Du C; Fries DF; Wong KK; Mesirov JP; Loeffler JS; Schreiber SL; Hammerman PS; Meyerson M
Cancer Res; 2013 Oct; 73(20):6289-98. PubMed ID: 23980093
[TBL] [Abstract][Full Text] [Related]
2. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
4. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.
Ji L; Moghal N; Zou X; Fang Y; Hu S; Wang Y; Tsao MS
Cancer Med; 2023 Mar; 12(5):5688-5702. PubMed ID: 36305267
[TBL] [Abstract][Full Text] [Related]
5. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses.
Lee S; Lim MJ; Kim MH; Yu CH; Yun YS; Ahn J; Song JY
Free Radic Biol Med; 2012 Aug; 53(4):807-16. PubMed ID: 22684019
[TBL] [Abstract][Full Text] [Related]
6. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
[TBL] [Abstract][Full Text] [Related]
7. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
Liu Z; Deng M; Wu L; Zhang S
Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
[TBL] [Abstract][Full Text] [Related]
8. A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer.
Lin SH; Zhang J; Giri U; Stephan C; Sobieski M; Zhong L; Mason KA; Molkentine J; Thames HD; Yoo SS; Heymach JV
J Thorac Oncol; 2014 Jul; 9(7):965-973. PubMed ID: 24922006
[TBL] [Abstract][Full Text] [Related]
9. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Pathological Characteristics of
Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
[No Abstract] [Full Text] [Related]
11. Increased NRF2 gene (NFE2L2) copy number correlates with mutations in lung squamous cell carcinomas.
Sasaki H; Shitara M; Yokota K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Mol Med Rep; 2012 Aug; 6(2):391-4. PubMed ID: 22614957
[TBL] [Abstract][Full Text] [Related]
12. Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines.
Schilling D; Bayer C; Emmerich K; Molls M; Vaupel P; Huber RM; Multhoff G
Strahlenther Onkol; 2012 Apr; 188(4):353-8. PubMed ID: 22318330
[TBL] [Abstract][Full Text] [Related]
13. NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells.
Guan L; Nambiar DK; Cao H; Viswanathan V; Kwok S; Hui AB; Hou Y; Hildebrand R; von Eyben R; Holmes BJ; Zhao J; Kong CS; Wamsley N; Zhang W; Major MB; Seol SW; Sunwoo JB; Hayes DN; Diehn M; Le QT
Cancer Res; 2023 Mar; 83(6):861-874. PubMed ID: 36652552
[TBL] [Abstract][Full Text] [Related]
14. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M
Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347
[TBL] [Abstract][Full Text] [Related]
15. Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report.
Nishimura R; Yoshida T; Torasawa M; Kashihara T; Ohe Y
Thorac Cancer; 2023 Jan; 14(2):206-209. PubMed ID: 36453575
[TBL] [Abstract][Full Text] [Related]
16. Multiomics Differences in Lung Squamous Cell Carcinoma Patients with High Radiosensitivity Index Compared with Those with Low Radiosensitivity Index.
Du Y; Yuan S; Zhuang X; Zhang Q; Qiao T
Dis Markers; 2021; 2021():3766659. PubMed ID: 34504628
[TBL] [Abstract][Full Text] [Related]
17.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic analyses of the radiation response in head and neck squamous cell carcinoma subclones with different radiation sensitivity: time-course gene expression profiles and gene association networks.
Michna A; Schötz U; Selmansberger M; Zitzelsberger H; Lauber K; Unger K; Hess J
Radiat Oncol; 2016 Jul; 11():94. PubMed ID: 27455841
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Bonelli MA; Cavazzoni A; Saccani F; Alfieri RR; Quaini F; La Monica S; Galetti M; Cretella D; Caffarra C; Madeddu D; Frati C; Lagrasta CA; Falco A; Rossetti P; Fumarola C; Tiseo M; Petronini PG; Ardizzoni A
Mol Cancer Ther; 2015 Aug; 14(8):1916-27. PubMed ID: 26013318
[TBL] [Abstract][Full Text] [Related]
20.
Binkley MS; Jeon YJ; Nesselbush M; Moding EJ; Nabet BY; Almanza D; Kunder C; Stehr H; Yoo CH; Rhee S; Xiang M; Chabon JJ; Hamilton E; Kurtz DM; Gojenola L; Owen SG; Ko RB; Shin JH; Maxim PG; Lui NS; Backhus LM; Berry MF; Shrager JB; Ramchandran KJ; Padda SK; Das M; Neal JW; Wakelee HA; Alizadeh AA; Loo BW; Diehn M
Cancer Discov; 2020 Dec; 10(12):1826-1841. PubMed ID: 33071215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
